Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 737

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 737
---
 2022, 2021 and 2020 | ​ | ​ | ​    | ​ | F-39 | ​ | ​ |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021                 | ​ | ​ | ​    | ​ | F-40 | ​ | ​ |
| Notes to Consolidated Financial Statements                                                                 | ​ | ​ | ​    | ​ | F-41 | ​ | ​ |

TVARDI THERAPEUTICS, INC.

| ​                                                                                                                           
 Report of Independent Registered Public Accounting Firm                                                                     
 Balance sheets as of December 31, 2023 and 2022                                                                             
 Statementsof Operations and Comprehensive Loss for the Years EndedDecember 31, 2023 and 2022                                | ​ 
 ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ | Page 
 ​    
 ​    
 ​    | ​ 
 ​ 
 ​ | F-89 
 F-91 
 F-92 | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ 
 ​ |
|:----------------------------------------------------------------------------------------------------------------------------|:--|:--|:-----|:--|:-----|:--|:--|
| Statements ofRedeemable Convertible Preferred Stock and Stockholders’ Deficit for the Years EndedDecember 31, 2023 and 2022 | ​ | ​ | ​    | ​ | F-93 | ​ | ​ |
| Statementsof Cash Flows for the Years EndedDecember 31, 2023 and 2022                                                       | ​ | ​ | ​    | ​ | F-94 | ​ | ​ |
| Notes toFinancial Statements                                                                                                | ​ | ​ | ​    | ​ | F-95 | ​ | ​ |

| ​                                                                                                                                                        
 Unaudited condensed balance sheets as of September 30, 2024 and December 31, 2023.                                                                       
 Unaudited condensed statements of operations for the nine months ended September 30, 2024 and2023                                                        | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Page 
 ​    
 ​    | ​ 
 ​ | F-115 
 F-116 | ​ 
 ​ | ​ 
 ​ 
 ​ |
|:---------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:--|:-----|:--|:------|:--|:--|
| Unaudited condensed statements of redeemable convertible preferred stock and stockholders’ deficit for the nine months ended September